No. 19-1131

Actavis Laboratories FL, Inc. v. Nalpropion Pharmaceuticals LLC

Lower Court: Federal Circuit
Docketed: 2020-03-16
Status: Denied
Type: Paid
Amici (1) Experienced Counsel
Tags: 35-usc-112 claim-construction federal-circuit patent-claims patent-law patent-law-35-usc-112 patent-specification patent-validity statutory-interpretation written-description written-description-requirement
Key Terms:
Antitrust Patent JusticiabilityDoctri
Latest Conference: 2020-05-21
Question Presented (AI Summary)

Whether § 112 requires a patent's specification to contain a written description of all of the limitations of a patent's claims, not just a 'substantially equivalent' disclosure

Question Presented (OCR Extract)

QUESTION PRESENTED Under 35 U.S.C. § 112, a patent’s specification must “contain a written description of the invention.” That requirement, a cornerstone of federal patent law, ensures that an inventor can claim patent protection only for what she actually invented. Consistent with this Court’s longstanding directive that every element of a patent claim must be treated as material, the Federal Circuit has long held that all elements of a patent’s claims must actually be disclosed in the patent’s specification. But the Federal Circuit has now broken from that established rule. In the 2-1 decision below, the Federal Circuit announced for the first time that for some claim limitations, a “substantially equivalent” disclosure will do. Here, although the claims expressly require testing using one specific method identified by name, the court held that the written description’s disclosure of a different testing method was good enough. The court grounded its change of heart not in statutory text or precedent, but in the court’s view that “[r]igidity should yield to flexible, sensible interpretation.” The question presented is: Whether § 112 requires a patent’s specification to contain a written description of all of the limitations of a patent’s claims, not just a “substantially equivalent” disclosure. i

Docket Entries

2020-05-26
Petition DENIED.
2020-05-05
DISTRIBUTED for Conference of 5/21/2020.
2020-05-04
Reply of petitioner Actavis Laboratories FL, Inc. filed. (Distributed)
2020-04-15
Brief amicus curiae of Association for Accessible Medicines filed.
2020-04-15
Brief of respondent Nalpropion Pharmaceuticals LLC in opposition filed.
2020-03-13
Petition for a writ of certiorari filed. (Response due April 15, 2020)

Attorneys

Actavis Laboratories FL, Inc.
William McGinley JayGoodwin Procter, LLP, Petitioner
William McGinley JayGoodwin Procter, LLP, Petitioner
Association for Accessible Medicines
Matthew S. HellmanJenner & Block LLP, Amicus
Matthew S. HellmanJenner & Block LLP, Amicus
Nalpropion Pharmaceuticals LLC
Dominick A. CondeVenable LLP, Respondent
Dominick A. CondeVenable LLP, Respondent